Amphastar Pharmaceuticals (AMPH) Net Cash Flow Growth (3y) (2016 - 2026)
Amphastar Pharmaceuticals (AMPH) Net Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Amphastar Pharmaceuticals | 938.56 Mn | 648.44 Mn | 93.47 Mn | 59.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.55% |
| Mar 31, 2026 | -64.72% |
| Dec 31, 2025 | -240.72% |
| Sep 30, 2025 | 73.77% |
| Jun 30, 2025 | 40.09% |
| Mar 31, 2025 | -12.47% |
| Dec 31, 2024 | -59.35% |
| Sep 30, 2024 | 28.96% |
| Jun 30, 2024 | -35.84% |
| Mar 31, 2024 | 96.63% |
| Dec 31, 2023 | -211.14% |
| Sep 30, 2023 | 613.36% |
| Jun 30, 2023 | -40.72% |
| Mar 31, 2023 | 45.76% |
| Dec 31, 2022 | 54.14% |
| Sep 30, 2022 | 36.56% |
| Jun 30, 2022 | -29.14% |
| Mar 31, 2022 | 103.06% |
| Dec 31, 2021 | 3.91% |
| Sep 30, 2021 | -41.85% |